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Parthenolide (PT) is a sesquiterpene lactone isolated from Tanacetum parthenium.
In this study, PT showed varying cytotoxic effects against different solid tumor cell
lines. HCT116 (p53+/+) colon carcinoma cells and their parental HCT116 knockout
p53 (p53−/−) cell lines showed a resistance degree of 2.36. On the other hand,
wild-type U87.MG cells or cells transfected with a deletion-activated EGFR cDNA
(U87.MG1EGFR) exhibited slight sensitivity toward PT. Multidrug-resistant MDA-MB-
231-BCRP cells were even more sensitive toward PT than sensitive MDA-MB-231-
pcDNA cells with a resistance degree of 0.07 (collateral sensitivity). To the best of
our knowledge, hypersensitivity (collateral sensitivity) in MDA-MB-231-BCRP cell line
is reported in this study for the first time. We attempted to identify the mechanism of
collateral sensitivity. Firstly, we found that PT bound to IKK preventing IκBα degradation
and eventually inhibition of the nuclear factor kappa B (NF-κB) pathway. Down-regulation
of hypoxia inducing factor 1-alpha (HIF-1α) in MDA-MB-231-BCRP resistant cells may
be a second mechanism, since it is a target gene of NF-κB. Moreover, PT also
showed epigenetic effect by inhibition of HDAC activity as shown using both molecular
docking and HDAC activity assay. Based on COMPARE and hierarchical cluster
analyses, we found gene expression profiles that predicted sensitivity or resistance
of 47 tumor cell lines toward PT. Interestingly, pathway analyses of gene expression
profiles revealed NF-κB and HIF signaling as top networks of these genes, cellular
functions and canonical pathways influencing the activity of PT against tumor cells.
In conclusion, PT exerted profound cytotoxic activity against various cancer cell lines
mainly against BCRP-overexpressing tumor cells, suggesting PT as novel candidate for
cancer treatment.
Keywords: drug resistance, chemotherapy, HDAC, natural products, NF-κB, pharmacogenomics, phytochemicals
Abbreviations: ABC, ATP-binding cassette; BCRP, breast cancer resistance protein; EGFR, epidermal growth factor
receptor; FBS, fetal bovine serum; HAT, histone acetylation; HDAC, histone deacetylase; PT, parthenolide; TP53, tumor
suppressor gene 53.
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INTRODUCTION
Parthenolide (PT) is a sesquiterpene lactone isolated from the
Mexican-Indian medicinal plant Tanacetum parthenium. It has
anti-inflammatory properties and is clinically used for migraine
treatment (Murphy et al., 1988; Bork et al., 1997). Moreover,
PT is nucleophilic in nature due to its lactone ring and epoxide
group. This feature explains, why PT exerts several biological
activities, such as anti-cancer activity by inducing extrinsic and
intrinsic pathways of apoptosis (Wen et al., 2002; Zhang et al.,
2004) without affecting normal cells (Mathema et al., 2012).
In addition, PT had a potent effect on both breast cancer stem
cells and breast cancer cells. PT suppressed overexpression of NF-
E2-related factor 2 (Nrf2) and its related genes that prevented
development of resistance to mitoxantrone and doxorubicin in
triple-negative breast cancer (Carlisi et al., 2017). PT inhibited
MCF-7 mammosphere formation and MCF-7 xenograft tumor
growth as well as elimination of breast cancer stem cells by NF-κB
pathway deactivation (Dandawate et al., 2016).
Despite the availability of numerous clinically established
standard cytostatic drugs, their effectiveness is largely hampered
by the development of resistance and severe side effects (Efferth
and Oesch, 2004; Kuczynski et al., 2013; Efferth, 2017). Multidrug
resistance (MDR) represents a main reason for chemotherapy
failure. Among the most important MDR mechanisms are
ATP binding cassette (ABC) proteins expressed on cancer cell
membranes (Efferth, 2001; Gillet et al., 2007; Boonyong et al.,
2017; Efferth and Volm, 2017; Umsumarng et al., 2017). BCRP
belongs to this family of eﬄux transporters responsible for drug
disposition and distribution. BCRP expression is significantly
associated with tumor response to chemotherapy and resistance
(Faneyte et al., 2002; Wu et al., 2018). Mutations in the EGFR also
confer drug resistance in non-small cell lung cancer (NSCLC)
and other tumor types (Cortot and Janne, 2014), e.g., the T790M
mutation, alternative pathways activation, loss of function of
the EGFR-mediated apoptosis pathway (Huang and Fu, 2015).
In addition, loss of tumor suppressor function such as p53
mutations also play an important role in drug resistance (Hientz
et al., 2017; Heo et al., 2018). P53 plays a key role in the regulation
of cell cycle arrest, DNA repair and apoptosis. Hence, it effectively
contributes to sensitivity toward anticancer drugs (Lowe et al.,
1993; Ferreira et al., 1999). A better understanding of the
molecular mechanisms underlying resistance to cancer drugs can
assist the design of new therapeutic drugs and the development
of better treatment strategies to overcome resistance.
Epigenetics plays an important role in tumorigenesis and
cancer development. It covers three different areas: DNA
methylation, histone modification and non-coding RNAs
(Sharma et al., 2010). Histones have a variety of posttranslational
modifications at specific residues to regulate DNA replication,
transcription and repair. These modifications include
methylation, acetylation, ubiquitylation, sumoylation, and
phosphorylation (Kouzarides, 2007). Histone acetyltransferase
(HAT) has a major impact on genes expression. HDAC
counteract HAT (Li and Seto, 2016). Many cancers exhibit
defects in the balance between HAT and HDAC activity,
which leads to transcriptional silencing of genes that control
differentiation, apoptosis, cell cycle arrest, etc. (Lakshmaiah et al.,
2014). Therefore, HDACs became an important target for the
development of new anticancer therapy.
The transcription factor nuclear factor kappa B (NF-κB)
represents a key player in tumorigenesis, because of its
mechanistic link to cell proliferation, survival, apoptosis, and
metastasis (Lin and Karin, 2003). NF-κB is inactive in the
cytoplasm through its binding to inhibitory proteins (IκB). Upon
activation by specific stimuli, IκB is phosphorylated by the IκB
kinase (IKK) complex. Then, activated NF-κB translocates to the
nucleus and binds specific nucleotide sequences at the promoter
region of downstream genes, which mediate the expression of
these genes (Baud and Karin, 2009). NF-κB target genes are for
instance the anti-apoptotic protein Bcl-2, Bfl-1, TNF-receptor
associated factors (TRAFs), Bcl-XL, Bcl-w, IAPs, c-FLIP, XIAP
and other genes (Pahl, 1999). NF-κB activation is also correlated
with the down-regulation of the pro-apoptotic proteins Bax and
Bad (Cao et al., 2013). The activity of NF-κB in hematologic
malignancies and different solid tumors has been associated with
anti-cancer drug resistance (Prasad et al., 2010; Luo et al., 2015).
Inhibition of NF-κB signaling represents an effective strategy
to improve the effectiveness of conventional anti-tumor drugs
(Longley and Johnston, 2005).
In the present study, we investigated the cytotoxic effect of
PT toward BCRP-transfected breast cancer cells, EGFR-mutated
brain cancer cells, and colon cancer cells with a knockout
mutation in the TP53. These cells exert resistance to conventional
anticancer drugs (Kuete et al., 2016, 2017). Therefore, we
were interested to find out, whether these drug-resistant cells
would be responsive to PT. To understand the mechanisms
of sensitivity or resistance of PT to cancer cells, microarray-
based mRNA expression profiles were analyzed. Furthermore, we
carried out NF-κB and HIF-α expression analyses and HDAC
inhibition assays.
MATERIALS AND METHODS
Cell Lines and Reagents
Cancer cell lines were routinely cultured in DMEM medium
supplemented with 10% FBS and 1% penicillin/streptomycin
(Invitrogen, Darmstadt, Germany) (Bunz et al., 1998;
Efferth et al., 2003).
Wild-type U87.MG cells and its transfected sublime
U87.MG1EGFR carrying an EGFR cDNA with a deletion
of exons 2–7 were obtained from Dr. W. K. Cavenee (Ludwig
Institute for Cancer Research, San Diego, CA, United States)
(Huang et al., 1997; Saeed et al., 2014). Breast cancer cells
transfected with control vector (MDA-MB-231-pcDNA) or with
cDNA encoding the BCRP (MDA-MB-231-BCRP clone 23) were
previously reported (Doyle et al., 1998). In addition, colon cancer
cell lines HCT-116 (p53+/+) and it counterparts knockout
clones (p53−/−) were kindly gifted by Dr. B. Vogelstein and
H. Hermeking (Howard Hughes Medical Institute, Baltimore,
MD, United States) (Bunz et al., 1998). The above mentioned
resistance cell lines were maintained in 800 ng/ml geneticin
(Sigma-Aldrich, Taufkirchen, Germany), in order to maintain
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the transcript. PT was purchased from Sigma-Aldrich. According
to the company instructions, it is HPLC level of more than 98%.
Cell Growth Inhibition Assay
The cytotoxicity of PT was evaluated using the resazurin
(Promega, Mannheim, Germany) reduction assay as previously
described (Kuete et al., 2016, 2017). Only viable cells can
reduce and convert resazurin to highly fluorescent resorufin,
while dead cells cannot convert resazurin dye (O’brien et al.,
2000). Based on this principle, tumor cells were treated with
different concentrations of PT and incubated for 72 h. An
Infinite M2000 Proplate reader (Tecan, Germany) was used to
measure the fluorescence using excitation/emission wavelength
of 544/590 nm. The 50% inhibition concentrations (IC50) were
determined using dose response curves of each cell lines using
Excel 2013 software (Microsoft, Redmond, WA, United States).
The experiments were conducted three times independently with
six replicates each.
The tumor cell line panel of the National Cancer Institute
(NCI, United States) was treated with PT and subjected to the
sulforhodamine B assay (Rubinstein et al., 1990).
COMPARE and Hierarchical Cluster
Analyses
The mRNA microarray data of 47 tumor cell lines of the
panel of the National Cancer Institute (NCI), United States
were subjected to COMPARE analyses to generate rank-ordered
lists of candidate genes related to sensitivity or resistance to
cytotoxic test compounds as previously reported (Paull et al.,
1989). Every gene was ranked for similarity of its mRNA
expression values to the log10IC50 values of PT, in order to create
scale index of correlation coefficients (R-values). Hierarchical
cluster analysis using the Ward method was applied to classify
the objects by calculation of distances based on the closeness
between-individual distances, resulting in tree clustering termed
dendrogram (Efferth et al., 1997; Scherf et al., 2000).
Hierarchical clustering and dendrogram analyses were
piloted using CIM miner software1. Importantly, COMPARE
analyses and Cluster models have been previously validated
for gene expression profiling and for approaching molecular
pharmacology of anti-tumor compounds. This method was
previously described by us in detail (Dawood et al., 2018).
BCRP ATPase Activity Assay
A colorimetric ATPase assay was carried out to test the effect
of PT on ABC transporters. Membranes with human BCRP
were purchased from Corning Life Sciences (NY, United States).
The assay was conducted following the manufacturer’s protocol.
We previously described the ATPase protocol in details (Ooko
et al., 2016; Hamdoun et al., 2017). Briefly, a reaction mixture
composed of membranes, PT concentration, MgATP and assay
buffer was incubated for 20 min at 37◦C. To stop the reaction,
10% SDS was added. Afterward, a color reagent was added
to the wells, in order to measure inorganic phosphate using
1https://discover.nci.nih.gov/cimminer/oneMatrix.do
Tecan Reader Infinite m200 Pro. The assay was performed in
triplicate. Nunc transparent flat-bottomed plates were used for
the measurements. Sulfasalazine was used as positive control.
Molecular Docking
Molecular docking is a predictive bioinformatical method to
evaluate the interaction of ligands with their target proteins.
The three-dimensional structure of PT was obtained from the
PubChem database using PT smiles (Simplified Molecular Input
Line Entry Specification), while the X-ray crystallography-based
three-dimensional structures for the desired target proteins were
downloaded from the Protein Data Bank2; the selected proteins
and their PDB ID’s are represented in Table 3.
Molecular docking was performed with AutoDock 4 by means
of a Lamarckian algorithm as previously described by our group
(Morris et al., 2009; Zeino et al., 2014). Protein structures were
initially processed with AutoDock Tools, in order to overcome
structural problems due to missing atoms or water. The PDBQT
output format was prepared. Then, a grid box was created
to direct the docking process. 250 runs and 2,500,000 energy
evaluations were set as docking parameters for each round. Visual
Molecular Dynamics (VMD) was carried out for visualization of
the interaction modes obtained from docking experiments (Zeino
et al., 2014; Kadioglu et al., 2015). Vorinostat and triptolide were
applied as control inhibitors for HDAC and NF-κB, respectively.
The experiments were performed three times and the mean of
the lowest binding energies and mean binding energies were
taken into account.
NF-κB Reporter Assay
NF-κB SEAP reporter HEK 293 were purchased from InvivoGen
(San Diego, CA, United States), in order to examine the effect
of PT on NF-κB. They express the secreted embryonic alkaline
phosphatase (SEAP) reporter gene under the regulatory sequence
of the NF-κB promoter.
HEK293 cells were culture in appropriate conditions as
previously described (Seo et al., 2016; Hamdoun and Efferth,
2017). HEK293 cells were treated with different concentrations
of PT followed by 100 ng/mL of tumor necrosis factor (TNF)
for 24 h to activate NF-κB. Pre-warmed Quanti-Blue reagent
(InvivoGen) was applied to measure SEAP levels using an Infinite
M2000 Pro plate reader at 630 nm. Triptolide (1 µM, InvivoGen)
was used as positive control. For these experiments, the assay was
repeated at least three times.
Protein Extraction
MDA-MB-231-pcDNA and MDA-MB-231-BCRP cells were
seeded in six-well plates and treated with different PT
concentrations (5, 10, and 25 µM). After 6 h incubation,
cells were washed with PBS and harvested in 1.5 ml Eppendorf
tubes. The total protein fraction was extracted using M-PER R©
Mammalian Protein Extraction Reagent (Thermo Fisher
Scientific, Germany) with protease inhibitor (1:100) and shaken
for 30 min at 4◦C. Then, cell lysates were centrifuged at 14,000× g
for 15 min at 4◦C. The supernatants were collected in clean tubes.
2http://www.rcsb.org/pdb
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Protein quantity and quality were measured by Nano-Drop 1000
(Thermo Fisher Scientific) (Hamdoun and Efferth, 2017).
SDS-PAGE and Western Blot Analysis
Thirty mg/ml were taken from the protein fraction, and SDS-
loading dye was added following by heating at 95◦C for 10 min.
After the denaturation process, proteins were loaded onto 10%
SDS-polyacrylamide gels. A Western blotting apparatus was
used to transfer proteins on a PVDF membrane (Roti R© PVDF,
pore size 0.45 µm, Carl Roth GmbH, Karlsruhe, Germany).
The membrane was blocked using 5% BSA/TBS-T and then
incubated with primary antibodies against NF-κB p65 (D14E12),
IκB (44D4), HIFα (D2U3T), or β-actin (13E5) overnight at a
dilution of 1:1000. HRP-linked secondary anti-rabbit antibody
(1:2000) was then added and incubated for 1 h. Both primary
and secondary antibodies were purchased from Cell Signaling
(Frankfurt am Main, Germany). Luminata Classico HRP Western
Blot substrate (Merck Millipore, Schwalbach, Germany) was used
for the detection step and membranes was visualized with aid
of Alpha Innotech FluorChem Q system (Biozym, Oldendorf,
Germany) (Saeed et al., 2015; Zhao et al., 2015).
HDAC Activity Assay
Histone deacetylase activity assay kit (free cell assay) were
purchased from Abcam (Cambridge, CB4 0FL, United Kingdom).
The assay was performed following the manufacturer’s
instructions to measure the activity of HDAC in the presence
or absence of PT. The assay measures the activity of crude
HDAC by the basic principle of changing an HDAC reaction
into peptidase activity. After incubation with the compounds
for at least 20 min at room temperature, fluorescence intensity
was read using Infinite M2000TM Pro plate reader (Tecan) at
Ex/Em = 355 nm/460 nm. DMSO was used as negative control,
while vorinostat and trichostatin were used as positive controls
(Xie et al., 2014). The experiments were repeated twice.
Ingenuity Pathway Analysis
A number of software programs and bioinformatical tools
have been developed to identify the relationship between
set of proteins and whether they contribute to specific
pathways. Examples are open access programs such as Kyoto
Encyclopedia of Genes and Genomes (KEGG) (Ogata et al.,
1999), WikiPathways and Reactome (Vastrik et al., 2007), while
other programs such as Pathway Studio and to Ingenuity Pathway
Analysis (IPA) are commercially available (Panguluri et al., 2013).
In the present manuscript, genes described and identified via
compare analysis as factors determining cellular responsiveness
to PT were subjected to IPA (Qiagen Bioinformatics, Redwood
City, CA, United States). Prior to the analysis, genes were
uploaded to IPA in Excel format. Core analyses were carried
out to identify canonical pathways, diseases and functions, and
relevant networks as described (Dawood et al., 2018).
Statistical Analysis
Pearson’s correlation test was applied to correlate microarray-
based mRNA expression of candidate genes with the IC50
values for PT. Hierarchical cluster analysis using Ward’s method
(WinSTAT program, Kalmia, Cambridge, MA, United States)
was also used. Student’s t-test using Microsoft Excel 2016 was
performed to calculate the statistical significance of PT effect
on NF-κB pathways, HDAC activity, ATPase activity and HIF-
α expression. P-values of less than 0.05 were considered as
significant. All data represent mean values ± SD of three
independent experiments.
RESULTS
We tested PT in cell models expressing three different
drug resistance mechanisms (mutant EGFR, knockout p53,
overexpression of BCRP) using resazurin reduction assays. The
degree of resistance was calculated by dividing the IC50 of
HCT116 knockout p53 cells (p53−/−) by the IC50 of parental
wild-type cells HCT116 (p53+/+). Only a weak cross-resistance
of the knockout HCT116 (p53−/−) cells was observed (2.36-
fold). In addition, U87.MG wild-type cells and their counterpart
glioblastoma cells transfected with a deletion-activated EGFR
cDNA (U87.MG.1EGFR) were investigated. U87.MG.1EGFR
cells exhibited a slight sensitivity toward PT with an IC50 value of
32.7± 3.8 µM, which was lower than the IC50 value of wild-type
U87.MG cells (46.0 ± 3.8 µM) (Table 1). Concerning the ABC-
transporter BCRP/ABCG2, it was an unexpected, but pleasing
result that the multidrug-resistant MDA-MB-231-BCRP cell line
was considerably more sensitive toward PT than sensitive MDA-
MB-231-pcDNA cells with a degree of resistance of 0.07 (Table 1).
The dose response curves are illustrated in Figure 1.
COMPARE and Hierarchical Cluster
Analyses
The transcriptome-wide mRNA expression of 47 cell lines from
different tumor types were correlated to the log10IC50 values for
PT. This bioinformatical COMPARE analysis based on Pearson’s
rank correlation test was applied to identify novel putative
molecular factors associated with cellular response to PT. The
top 20 genes positively correlating with log10IC50 values more
than R = 0.50 and the top 20 genes negatively correlating with
log10IC50 values less than R = −0.50 negative are summarized in
Table 2 together with their specific cellular functions.
TABLE 1 | Cytotoxic effect of parthenolide toward different cancer cell lines.
Cell lines Parthenolide
IC50 (µM) Degree of resistance
HCT116 p53+/+ 17.6 ± 1.8 2.36
HCT116 p53−/− 41.6 ± 1.2
U87.MG 46.0 ± 3.8 0.77
U87.MG 1EGFR 32.7 ± 3.8
MDA-MB-231 pc DNA 115.8 ± 2.3 0.07
MDA-MB-231 BCRP 08.5 ± 1.3
The IC50 values were shown as mean values ± SD of triplicate experiments with
each six parallel measurements.
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FIGURE 1 | (A) Chemical structure of parthenolide. (B–D) Cytotoxicity of parthenolide toward sensitive and drug-resistant tumor cell lines as measured by the
resazurin reduction assay. Experiments have been performed as triplicates.
Hierarchical cluster analysis (cluster image mapping) was
conducted for these selected genes. The examined 47 NCI
cell lines are depicted on the right side of the heat map
(dendrogram), while the 40 genes are placed on the bottom
of the heat map (Figure 2A). The cell lines can be divided
into four major clusters. The first cluster contained six cell
lines, the second and third clusters contained each 14 cell
lines, and the fourth cluster consisted of another 13 tumor
cell lines. Using the chi-square test, we investigated whether
the scattering of these cell lines being sensitive or resistant
toward PT was significantly different between these four clusters.
We found a p-value of 3.86 × 10−3 (Figure 2B), indicating
that sensitivity or resistance of tumor cell lines to PT was
predictable by using this gene expression profile. The identified
genes belong to different functional classes such as cell cycle
and growth (E2F3, NOLC1, and PTPRK), signal transduction
(ANXA2, IGFBP4, IL27RA, RGS19, and RPL17), transcription
and translation (HIF1A, NACA, NVL, EMG1, POLR3C, and
RPL17), development and differentiation (ARHGAP4, CLPTM1,
and PDLIM5), and apoptosis (RRP1B, HIF1A, etc.).
ATPase Activation of BCRP Transporter
To understand why BCRP-overexpressing cells revealed collateral
sensitivity to PT, we evaluated the effect of PT on the ATPase
activity of BCRP. Human BCRP spotted onto membranes was
used to conduct ATPase assays with or without PT treatment.
Sulfasalazine, which is known to activate ATPase activity of
the BCRP transporter served as positive control. In contrast
to sulfasalazine, PT showed statistically insignificant effect on
ATPase activity of BCRP in a dose-dependent manner (Figure 3).
In silico Binding of PT to HDAC and
NF-κB Proteins
Three deregulated genes (E2F3, HIF-α, BCRP) identified by
COMPARE analysis in the NCI cell line panel were previously
described as downstream target genes of NF-κB (Cheng et al.,
2003; Viturro et al., 2006; Belaiba et al., 2007; Bonello et al.,
2007). Based on this finding, we performed molecular docking
of PT with IκB kinase, IκB kinase-NEMO complex and NF-κB-
DNA (p65/p50) complex (Figure 4). PT strongly bound with a
binding energy of −8.08 ± < 0.001 kcal/mol to IκK-NEMO and
to NF-κB (RelB/p52) with −7.54 ± < 0.001 kcal/mol. Table 3
shows the lowest binding energies for the three proteins and the
amino acids residues involved in the interaction with PT. Bold
amino acids presented the residues that are involved in hydrogen
bond interaction with the compounds. PT showed comparable
binding energies to the known NF-κB inhibitor triptolide and
with even lower binding energies than triptolide to IκB kinase.
Both compounds docked to the same binding site (Figure 4).
In addition, we performed molecular docking for PT against
HDAC. Docking experiments revealed that PT bound to HDAC
with a binding energy of −6.52 ± < 0.001 kcal/mol, remarkably,
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TABLE 2 | Correlation coefficients of mRNA expression to log10 IC50 values obtained using COMPARE analyses for 47 NCI cancer cell lines and genes function obtained
from gene cards and gene atlas databases.
Gene Symbol Gene name Gene function
RRP1B Ribosomal RNA processing 1 homolog B (S. cerevisiae) Metastasis, modulator of transcription and chromatin, role in the regulation of gene,
induction of apoptosis.
EMG1 EMG1 nucleolar protein homolog (S. cerevisiae) Ribosomal subunit biogenesis.
NPM3 Nucleophosmin/nucleoplasmin 3 Inhibits histone assembly activity of NPM1 and dramatically enhances transcription.
This protein likely functions as a molecular chaperone in the cell nucleus.
COIL Coilin
ARHGAP4 Rho GTPase activating protein 4 Inhibition of stress fiber organization. Role in lymphocyte differentiation. Cell
organization/biogenesis.
RPL18A Ribosomal protein L18a Protein translation and synthesis.
PDCD11 Programmed cell death 11 NF-κB (NFKB1; 164011)-binding protein. Required for rRNA maturation and
generation of 18S rRNA.
IL27RA Interleukin 27 receptor, alpha Receptor for IL27. Can trigger signaling in T cells, B cells, and myeloid cells.
POLR3C Polymerase (RNA) III (DNA directed) polypeptide C (62 kD) Nucleotide transcription regulation.
RPL36A Transcribed locus, strongly similar to NP_775369.1 60S
ribosomal protein L36a
Ribosomal protein. Role in tumor cell proliferation.
NOLC1 Nucleolar and coiled-body phosphoprotein 1 Cell cycle, division, mitosis.
RPL17 Ribosomal protein L17 Signaling function.
E2F3 E2F transcription factor 3 Transcription repression in quiescent cell by interaction with histone deacetylase. Cell
cycle.
RGS19 Regulator of G-protein signaling 19 Inhibiting signal transduction.
GNL2 Guanine nucleotide binding protein-like 2 GTPase that associates with pre-60S ribosomal subunits in the nucleolus and is
required for their nuclear export and maturation.
RBM34 RNA binding motif protein 34 RNA recognition motif protein.
PPRC1 Peroxisome proliferator-activated receptor gamma,
coactivator-related 1
Involved in mitochondrial proliferation.
NACA Nascent polypeptide-associated complex alpha subunit Transcriptional co-activator.
FAM216A Family with sequence similarity 216 member A Unknown.
NVL Nuclear VCP-like ATP-dependent zinc metallopeptidase. Role in ribosome biosynthesis. Essential for
telomerase biogenesis.
CLPTM1 Cleft lip and palate associated transmembrane protein 1 Function in developmental processes.
PTPRK Protein tyrosine phosphatase, receptor type, K Regulation of processes involving cell contact and adhesion such as growth control,
tumor invasion. and metastasis.
CRELD1 Cysteine-rich with EGF-like domains 1 Role in valvuloseptal morphogenesis.
CTNND1 Catenin (cadherin-associated protein), delta 1 RNA Role in cell structure and adhesion.
PDLIM5 PDZ and LIM domain 5 Role in cytoskeleton organization, cell lineage specification, organ development, and
oncogenesis. Actin-associated protein acting as a cytoplasmic retention factor for
ID2.
ZBTB20 Zinc finger and BTB domain containing 20 Transcription factor involved in hematopoiesis, oncogenesis, and immune responses.
ALDH3A2 Aldehyde dehydrogenase 3 family, member A2 Catalyzing the oxidation of medium-chain (fatty) aliphatic and aromatic aldehydes to
fatty acids. Detoxification of aldehydes generated by alcohol metabolism and lipid
peroxidation.
IGFBP4 Insulin-like growth factor binding protein 4 Alters the interaction of IGFs with cell surface receptors.
MEGF8 Multiple EGF-like-domains 8 Intracellular trafficking.
PALLD Palladin, cytoskeletal associated protein Targeting ACTN to specific subcellular foci.
SIM2 Single-minded homolog 2 (Drosophila) Role in the development of central nervous system.
ECE1 Endothelin converting enzyme 1 Poteolytic processing of endothelin precursors to biologically active peptides.
MYRF Myelin regulatory factor Role for the generation of mature myelin-gene-expressing oligodendrocytes within the
CNS.
SNAP25 Synaptosomal-associated protein, 25 kDa Role in the synaptic function of specific neuronal systems.
HIF1A Hypoxia inducible factor 1, α subunit (basic helix-loop-helix
transcription factor)
Master regulator of cellular and systemic homeostatic response to hypoxia by
activating transcription of many genes.
B4GALT4 UDP-Gal:β GlcNAc β 1,4-galactosyltransferase, polypeptide 4 Role in glycosphingolipid biosynthesis.
ANXA2 Annexin A2 Role in the regulation of cellular growth and in signal transduction pathways.
ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 ABC transporter, traffic ATPase. Role in the transport of biliary and intestinal excretion
of organic anions.
ANXA2P3 Annexin A2 pseudogene 3 Unknown.
RBP4 Retinol binding protein 4, plasma Delivery of retinol from the liver stores to peripheral tissues.
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FIGURE 2 | (A) Heat map obtained by hierarchical cluster analysis of transcriptome-wide expression profiling of 47 NCI tumor cell lines correlating to sensitivity and
resistance toward parthenolide. (B) Clusters of NCI tumor cell lines gained by hierarchical cluster analyses for parthenolide. The median log10 IC50 value (M) for
parthenolide was used as cut-off to classify tumor cell lines as being “sensitive” or “resistant.”
this interaction was lower compared to vorinostat a well-known
HDAC inhibitor (Figure 4).
PT Inhibit NF-κB Pathway
The NF-κB pathway plays a vital role in the activation of
genes associated with cell proliferation, angiogenesis, metastasis
and suppression of apoptosis. Thereby, this pathway promotes
oncogenesis (Xia et al., 2014). It also induces drug resistance in
cancer cells (Ahmed et al., 2013).
To confirm the molecular docking of PT to NF-κB, we
investigated the inhibitory effect of PT toward NF-κB using
a SEAP-driven NF-κB reporter cell line. The HEK Blue Null
1 cells were treated with different concentrations of PT or
triptolide as well-known NF-κB inhibitor (Yinjun et al., 2005).
Cells treated with DMSO served as negative control. As shown
in Figure 5, PT significantly inhibited NF-κB activity in a dose-
dependent manner.
Protein Expression Analysis
Western blot analysis revealed that PT inhibited NF-κB and
HIF-α expression in a dose-dependent manner. Assuming
that this may explain the collateral sensitivity of the BCRP
overexpressing cells to PT, three different concentrations of PT
were applied (5, 10, and 25 µM). Figure 6 showed that NF-κB
and HIF-α expression was statistically significant downregulated
in multidrug-resistant MDA-MB-231-BCRP cells in comparison
to their sensitive counterpart, MDA-MB-231-pcDNA.
HDAC Activity Assay
To confirm the data obtained from molecular docking of PT
to HDAC, we investigated whether PT may possess HDAC
inhibitory activity using free cell assay. PT significantly inhibited
nuclear HDAC activity at 5 and 20 µM. The known inhibitors
vorinostat and trichostatin, which served as positive controls, also
significantly inhibited nuclear HDAC (Figure 7).
Bioinformatic Analysis
The microarray data of the COMPARE analysis were subjected
to IPA. These genes contributed to important cellular functions
and diseases, e.g., cell morphology, cellular development,
cellular growth and proliferation, cellular movement, cell death,
carbohydrate metabolism, cancer, etc. (Figure 8). On the
other hand, the IPA analysis showed important canonical
pathways, such as PXR/RXR activation, osteoarthritis pathway,
phenylethylamine degradation, EIF2 signaling, phenylalanine
degradation, etc. (Figure 9). Interestingly, IPA network analysis
showed the NF-κB and HIF-α pathways (Figure 10) as well as
apoptosis genes (Figure 11).
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FIGURE 3 | Effect of parthenolide on ATPase activity of BCRP.
BCRP-expressing membranes were used to evaluate the inorganic phosphate
release from ATP as indicator of ABCG2 transporter activity. Four different
concentration were used (5, 10, 25, and 50 µM), and sulfasalazine was used
as positive control (known ATPase activator of BCRP transporter). ATPase
activity (nmol/min/mg protein) was measured as compared to DMSO control.
Asterisks (∗∗) indicates the statistical significant induction of ATPase (p < 0.01)
in compared to DMSO-treated control cells.
DISCUSSION
In the present study, we undertook an attempt to better
understand the multi-target function of PT in the context of
drug resistance to established cancer drug. Therefore, we tested
three drug resistance phenotypes; EGFR-mutated brain cancer
cells (as example of an oncogene), knockout p53 colon cancer
cells (as an example of a tumor suppressor gene) and BCRP-
transfected breast cancer cells (as an example of a multidrug
resistance-mediating ABC transporter). Interestingly, PT showed
not only profound cytotoxicity toward these drug-resistant cell
lines, but also toward a panel of 47 cell lines of different tumor
types. To the best of our knowledge, the collateral sensitivity
of BRCP-overexpressing tumor cells to PT is reported here
for the first time. Several other studies showed the potential
of PT to combat other drug resistance phenotypes. Carlisi
et al. (2015) showed that PT prevented drug resistance to
mitoxantrone and doxorubicin in MDA-MB231 cells. In another
study by Li et al. (2018), PT reversed drug-resistance of human
cisplatin-resistant gastric carcinoma cells (SGC-7901/DDP) cells
by inhibiting the signal transducer and activator of transcription
3 (STAT3) signaling pathway, increasing the expression of BAX
and p53, cleaving caspase-3 and caspase-9, and decreasing Bcl-
2 and Bcl-xL expression levels. On the other hand, it also
affected cell cycle through increasing cyclin-dependent kinase
inhibitor 1 expression and decreasing cyclin D1 expression
(Li et al., 2018).
The cytotoxicity of PT found in our analysis has been
confirmed by other investigations. PT caused cells death in
SW620 cells by inhibiting migration/invasion proteins such
as E-cadherin, β-catenin, vimentin, Snail, cyclooxygenase-2,
matrix metalloproteinase-2 (MMP-2), and MMP-9 as well as by
activating caspase-3 (Liu et al., 2017). It also showed growth
inhibitory effects of human cervical cancer (SiHa), breast cancer
(MCF-7) cell lines (Al-Fatlawi et al., 2015), non-small cell lung
FIGURE 4 | Molecular docking of parthenolide and known inhibitors of the NF-κB pathway and HDAC2. Macromolecules have been represented in new cartoon
format, while PT was represented in red. The known NF-κB inhibitor triptolide is shown in green using Visual Molecular Dynamics (VMD) software. (A) Docking poses
of the IKK pharmacophore (PDB code: 3R2F) in pink color. (B) Docking poses of the pharmacophore of NF-κB DNA complex (PDB code: Ivkx) in brown color.
(C) Docking poses of the pharmacophore of IKK nemo (PDB code: 3BRT) in green. (D) Docking poses of the HDAC2 pharmacophore (PDB code: 5IWG) in blue.
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TABLE 3 | Molecular docking results of parthenolide and known inhibitors of NF-κB and HDAC2.
Mean binding
energy (kcal/mol)
pKi (µM) Pharmacophore No. of
H bond
IκK
Parthenolide −6.52 16.53 ± 0.011 GLY384, ALA356, GLY355, LEU386, ASP385, LEU312, TRY370, VAL371,
ILE370
0
Triptolide −5.46 98.98 ± 0.18 GLN355, ASP358, GLY384, ILE372, VAL371, LEU312, LEU386, TRY370 2
IκK-NEMO
Parthenolide −8.08 1.19 MET734, GLU89, GLN730, GLN86, PHE82, ASN732, GLU729, LYS90,
GLU89, GLN86, ARG87
1




Parthenolide −5.12 177.46 ± 0.16 SER281, GLU282, LEU194, LYS195, GLU193 2
Triptolide −5.17 ± 0.12 164 ± 31.5 ARG30, GLU193, GLU279, LEU280, SER281, GLU282, PRO283, GLN271 2
HDAC
Parthenolide −6.59 ± 0.17 15.14 ± 4.57 Asp351, Arg312, Ile350, Ser351, Asn312, Arg311, Gly273, Pro344 2
Vorinostat −8.03 ± 0.21 1.36 ± 0.44 Phe210, Tyr209, His183, His146, Gly154, His145, Met35, Cys156, Gly306,
Leu144, Gly143, Try306
2
Binding energies and predicted inhibition constants (pKi) are represented as mean ± SD. Amino acids in bold are involved in hydrogen bonding.
cancer (GLC-82) (Lin et al., 2017), immortalized keratinocytes
HaCaT and melanoma cells A375 (George et al., 2016).
Several mechanisms have been proposed to explain collateral
sensitivity in ABC membrane transporter-expressing cells. From
P-glycoprotein (ABCB1/MDR1), it is known that collateral
sensitivity is caused by strong binding of the drug to the ABC
transporter, which leads to ATP hydrolysis by the drug pump.
Since the drug is not pumped out, another ATP is cleaved –
again without success. The futile cycling of ATP hydrolysis leads
to preferential ATP depletion and ultimately preferential death
of P-glycoprotein expressing cells compared to P-glycoprotein-
negative sensitive wild-type cells. Therefore, we tested the
ATPase activity of BCRP (ABCG2) after treatment with PT.
However, ATPase activity was not changed upon PT treatment
FIGURE 5 | Inhibition of NF-κB activity using HEK-BlueTM cells. Three
different parthenolide concentrations (15, 50, and 70 µM) and 1 µM triptolide
(TP) were used. The quantification was carried out after 24 h incubation. The
results are shown as mean values ± SD of three independent experiments.
Asterisks (∗∗) indicates statistical significant inhibition (p < 0.01) while three
asterisks (∗∗∗) indicate statistical significant (p < 0.001) compared to
DMSO-treated control cells.
of MDA-MB-231 BCRP transfected cells. This indicates that
the most common mechanism of collateral sensitivity in
P-glycoprotein-expressing cells did not apply to BCRP-expressing
MDA-MB-231-BCRP cells used in the present investigation.
To further study the collateral sensitivity of MDA-MB-231-
BCRP cells to PT, we focused on NF-κB (Bork et al., 1997;
Hayashi et al., 2010), which represents an important target
for cancer therapy with more than 700 identified as NF-κB
inhibitors, including PT (Gupta et al., 2010). Our molecular
docking results showed that PT bound to Iκk with high binding
energy, indicating that IκBα phosphorylation may be inhibited.
This may results in decreased NF-κB p65 expression via blocking
the phosphorylation and degradation of inhibitor of κB-α (IκBα)
(Baud and Karin, 2009). We validated the bioinformatical
docking using NF-κB reporter assays and Western blotting.
Statistically, we found that NF-κB in MDA-MB-231-BCRP was
more inhibited than in the sensitive MDA-MB-231 cells.
PT inhibited nuclear factor-κB (NF-κB) signaling (Bork et al.,
1997; Hehner et al., 1998; Kishida et al., 2007; Oka et al., 2007).
It promotes apoptotic mediated cell death and inhibits NF-κB
through the IkB kinase inhibition and/or direct modification of
p65 protein (Liu et al., 2010; Kanthan et al., 2012). Transcription
of pro-apoptotic genes was suppressed as a result of NF-
κB and STAT-inhibition by PT. NF-κB phosphorylation was
downregulated in gastric cancer cell lines (MKN-28, MKN-45,
and MKN-74) upon PT treatment (Sohma et al., 2011). PT
inhibited Iκk resulting in IκBα degradation and subsequent NF-
κB pathway inactivation (Hehner et al., 1998; Hehner et al.,
1999; Saadane et al., 2007). PT treatment induced apoptosis by
inhibition of NF-κB in colitis-associated colon cancer (Kim et al.,
2015). Wang et al. (2010) identified a NF-κB consensus binding
site within the BCRP promoter and validated this bioinformatical
result using EMSA assay in MCF-7 cells. This study further
supports our findings that PT preferentially inhibited NF-κB in
BCRP overexpressing cells leading to collateral sensitivity.
Frontiers in Pharmacology | www.frontiersin.org 9 May 2019 | Volume 10 | Article 542
fphar-10-00542 May 17, 2019 Time: 16:30 # 10
Dawood et al. Parthenolide Against Cancer Drug-Resistance
FIGURE 6 | Western blot analysis of NF-κB, IκB, and HIF-1α in parthenolide-treated multidrug-resistant MDA-MB-231-BCRP and sensitive MDA-MB-231-pcDNA3
cell lines (A) represents protein analysis for MDA-MB-231-BCRP while (B) represents protein analysis for MDA-MB-231-pcDNA. Cells were incubated with 5, 10,
and 25 µM parthenolide and DMSO as negative control for 6 h. Then, total protein was extracted and Western blotting was performed. The chart shows the change
in the protein expression after normalization to β-actin as mean ± SD for two independent experiments. Asterisk (∗) indicates statistical significant inhibition
(p < 0.05) while two asterisks (∗∗) indicate statistical significant (p < 0.01) compared to DMSO-treated control cells.
FIGURE 7 | Determination of histone deacetylase (HDAC) activity upon
treatment with three parthenolide concentrations. The known HDAC inhibitors
vorinostat and trichostatin were used as control compounds at a
concentration of each 10 µM. Asterisk (∗) indicates statistical significant
inhibition (p < 0.05) while two asterisks (∗∗) indicate statistical significant
(p < 0.01) compared to DMSO-treated control cells.
In addition to apoptosis induction through NF-κB, HIF-α
is also related to drug resistance, and it is a target of NF-κB
too (Gorlach and Bonello, 2008; Xia et al., 2018). Our findings
showed that PT inhibited HIF-α in multidrug-resistant BCRP-
expressing cells more than in their sensitive counterpart. The
preferential inhibition of HIF-α expression by PT in MDA-
MB-231-BCRP may, therefore represent a second mechanism of
collateral sensitivity.
Solid tumors frequently contain hypoxic regions, as they
grow more rapidly than blood supply can follow. In order
to overcome this problem, tumor cells activate a cellular
hypoxia program making them not only resistant to low
oxygen supply but also against chemotherapy. Several studies
indicated that HIF-α expression is vital for tumor survival (El
Guerrab et al., 2017). Therefore, it represents an attractive target
for cancer therapy (Koh et al., 2010). HIF-α expression was
significantly correlated with P-glycoprotein expression. Hypoxia
diminishes sensitivity to chemotherapy drugs by cell cycle
arrest, inhibition of apoptosis, lowering pH value, induction of
distant metastasis and cellular metabolism alteration (Mahoney
et al., 2003; Xu et al., 2017; Xia et al., 2018). Several
studies showed that PT inhibited HIF-1α. PT also suppressed
the epithelial-mesenchymal transition of metastasizing tumors
(Kim et al., 2017). Furthermore, PT significantly inhibited
HIF-α activity and angiogenesis through inhibition of the
NF-κB pathway.
Epigenetics is the process of inherited alterations in gene
expression without change in DNA sequence (Lakshmaiah et al.,
2014; Dawood and Efferth, 2015). HAT that occur at the
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FIGURE 8 | Biological functions affected by parthenolide as determined by mRNA microarray hybridization and Ingenuity Pathway Analysis.
FIGURE 9 | Canonical pathways identified using Ingenuity Pathway Analysis. P-values were determined by Fisher’s right tailed exact test. Y-axis of the bar showed
–log (p-value). The different color bars represent the pathway status orange bars are active predicted pathways while blue bars are the inhibited one. In this chart
only significant results was represented. Gray bars showed pathways, where no prediction can be applied.
lysine residue of histone proteins activates the transcription
of the genes. This process is carried out by histone acetyl
transferase (HAT), while HDAC function antagonistically by
removing the modification and lead to the negative result of gene
transcription (Bannister and Kouzarides, 2011). HDACs exhibit a
pro-oncogenic effect though transcriptional inactivation of genes,
which are involved in cell differentiation, apoptosis and cell cycle
arrest. Therefore, HDAC inhibition is an attractive target for
cancer therapy. HDAC inhibitors become a novel and promising
class of anti-cancer drugs. They have complex effects on cellular
processes (cell cycle arrest, inhibition of DNA repair, induction of
apoptosis) by activating transcription of tumor suppresser genes.
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FIGURE 10 | IPA network analyses of the 40 deregulated genes that we obtained from COMPARE analysis (see Table 2) revealed the reconstruction of (A) NF-κB
network pathway and (B) HIF-1α network.
FIGURE 11 | Set of 17 genes involved in apoptosis regulation as identified by COMPARE analysis and IPA analyses.
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FIGURE 12 | Schematic diagram presenting collateral sensitivity induced by
parthenolide. BRCP transfected cells showed shows collateral sensitivity
toward parthenolide by IKK inhibition, which prevented IκBα degradation and
inhibited NF-κB. In addition, parthenolide also inhibited HDAC activity. HDAC
stabilizes HIF-α. Decreasing the HIF-1α level activates apoptosis signaling
pathways. NF-κB inhibition leads to downregulation of BCRP and HIF-1α and
eventually to collateral sensitivity.
Vorinostat and romidepsin are Food and Drug Administration-
approved HDAC inhibitors for treatment of T-cell lymphoma
(Giannini et al., 2012; Khan and La Thangue, 2012). However,
they have the disadvantage that tumor cells frequently develop
resistance to these drugs. Therefore, novel HDAC inhibitors with
improved features are required.
In our experiments, PT significantly inhibited HDAC activity
at concentrations of 5 and 20 µM in comparison to DMSO-
treated control cells. To the best of our knowledge, this is the first
time to report that PT inhibits HDAC activity. The combination
of PT and the pan-HDAC inhibitors vorinostat or LBH589
blocked phosphorylation/activation of IKK and RelA/p65 and
activation of JNK1 in human acute myeloid leukemia cells.
Interestingly, PT increased HDAC inhibitor-mediated apoptosis
in hematopoietic cells through NF-κB inhibition (Dai et al.,
2010). Co-administration of PT and HDAC inhibitors caused
depletion of glutathione (GSH), release of cytochrome c, caspase
3 activation and apoptosis in MDA-MB-231 breast cancer cells
(Carlisi et al., 2015). Activation of IKK2 promoted HDAC1
protein depletion (Gopal and Van Dyke, 2006; Vashisht Gopal
et al., 2006). On the other hand, PT caused HDAC1 depletion
by the DNA-damage-transducer ataxia telangiectasia mutated
protein (Gopal et al., 2007).
Recently, several investigations reported that HDAC
inhibitors reduced HIF function in tumor cells (Kim et al., 2001;
Jeong et al., 2002; Mie Lee et al., 2003). HDAC stabilized HIF-α
by decreasing the expression of VHL and p53 (Kim et al., 2001).
These proteins mediated HIF-α degradation. HDACi activated
transcription of VHL and p53. Moreover acetylation of Lys532
of HIF-α stimulated its interaction with ubiquitination by VHL
(Jeong et al., 2002). TSA and FK228 induce HIF-α degradation
in VHL-null RCC4 cells (Demidenko et al., 2005) as well as
Caki, Hep3B, DU145, PC3, U87, BT20, MCF7, and particularly,
VHL−/− cells such as RCC4 and C2 (Liang et al., 2006).
Bioinformatics was used to identify molecular mechanism
of PT. COMPARE and hierarchical cluster analyses showed
important cellular processes determining the sensitivity
or resistance of tumor cells toward PT. Furthermore, we
wanted to investigate, that NF-κB, HIF and their related
networks are relevant to other cancer cell lines and not only
MDA-MB-231-BCRP.
We subjected the data obtained from COMPARE analysis to
IPA. Interestingly, IPA indeed revealed that many of the identified
genes were related to NF-κB and HIF signaling networks.
This further strengthens the importance of NF-κB and HIF
as mechanism to explain the cytotoxic activity of PT against
cancer cells. This result also fits together with the fact that we
found many apoptotic genes, which are regulated by NF-κB and
HIF. Furthermore, PT downregulated the expression of protein
involved in glucose metabolism, angiogenesis, development and
survival, all of which are regulated by HIF-α (Kim et al., 2017).
Not surprisingly, carbohydrate metabolism appeared as one of
the top signaling pathways using IPA analysis. The analysis
further showed important cellular mechanisms such as cell
cycle, cell death, cellular movement, cancer and other signaling
pathways, which are directly or indirectly connected to NF-
κB and HIF pathways. In addition, other pathways appeared
illustrating the complexity of cellular responses to PT.
In conclusion, PT was active against various sensitive
and drug-resistant cancer cell lines. In particular, BCRP-
overexpressing MDA-MB-231-BCRP were collateral sensitive
toward PT. Further investigations were carried out to understand
the mechanism of collateral sensitivity (Figure 12). PT as known
NF-κB inhibitor possesses also HDAC inhibitory activity, which
both leads to inhibition of HIF-α. This phenomenon is suggested
as mechanism of collateral sensitivity. COMPARE and cluster
analyses predicted the sensitivity or resistance of cancer cells to
PT using 47 NCI cell lines. Using a pathway analysis approach,
we identified cellular functions and canonical pathways of genes
involved in the mechanisms of action of PT.
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